Vanguard Group Inc. Buys 168,667 Shares of Amicus Therapeutics, Inc. $FOLD

Vanguard Group Inc. increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 29,702,696 shares of the biopharmaceutical company’s stock after purchasing an additional 168,667 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of Amicus Therapeutics worth $422,966,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. William Blair Investment Management LLC boosted its holdings in Amicus Therapeutics by 7.6% during the 3rd quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock valued at $124,104,000 after acquiring an additional 1,107,083 shares during the period. Vestal Point Capital LP boosted its holdings in Amicus Therapeutics by 178.4% during the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after acquiring an additional 7,625,000 shares during the period. State Street Corp boosted its holdings in Amicus Therapeutics by 21.5% during the 2nd quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after acquiring an additional 2,049,078 shares during the period. Bank of America Corp DE boosted its holdings in Amicus Therapeutics by 20.7% during the 2nd quarter. Bank of America Corp DE now owns 6,847,275 shares of the biopharmaceutical company’s stock valued at $39,235,000 after acquiring an additional 1,172,596 shares during the period. Finally, Qube Research & Technologies Ltd boosted its holdings in Amicus Therapeutics by 223.9% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock valued at $19,865,000 after acquiring an additional 2,396,410 shares during the period.

Analyst Ratings Changes

FOLD has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Friday, March 27th. Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Finally, Jefferies Financial Group restated a “hold” rating and set a $14.50 price objective (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.56.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 22,500 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $14.35, for a total value of $322,875.00. Following the transaction, the chief executive officer directly owned 998,680 shares of the company’s stock, valued at approximately $14,331,058. This represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $14.49 on Thursday. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $14.50. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of -181.13 and a beta of 0.48. The stock has a fifty day simple moving average of $14.42 and a two-hundred day simple moving average of $12.81. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. Amicus Therapeutics’s quarterly revenue was up 23.7% compared to the same quarter last year. On average, analysts predict that Amicus Therapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.